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SUMMARY
Innate lymphoid cells (ILCs) represent innate versions of T helper and cytotoxic T cells that differentiate from committed ILC precursors (ILCPs). How ILCPs give rise to mature tissue-resident ILCs remains unclear. Here, we identify circulating and tissue ILCPs in humans that fail to express the transcription factors and cytokine outputs of mature ILCs but have these signature loci in an epigenetically poised configuration. Human ILCPs robustly generate all ILC subsets in vitro and in vivo. While human ILCPs express low levels of retinoic acid receptor (RAR)-related orphan receptor C (RORC) transcripts, these cells are found in RORC-deficient patients and retain potential for EOMES + natural killer (NK) cells, interferon gamma-positive (IFN-g + ) ILC1s, interleukin (IL)-13 + ILC2s, and for IL-22 + , but not for IL-17A + ILC3s. Our results support a model of tissue ILC differentiation (''ILC-poiesis''), whereby diverse ILC subsets are generated in situ from systemically distributed ILCPs in response to local environmental signals.
INTRODUCTION
Innate lymphoid cells (ILCs) are a novel family of lymphoid effector cells that serve essential roles in the early immune response, comprising both ''cytotoxic'' ILCs (natural killer [NK] cells) and ''helper'' ILCs. The latter are characterized by CD127 expression and categorized as three groups based on transcription factors (TFs) and cytokine outputs. Group 1 innate lymphoid cells (ILC1s) express TBX21 (encoding T-BET) and produce T helper (T H )1-associated cytokines interferon gamma (IFN-g) and tumor necrosis factor alpha (TNF-a). Group 2 ILCs (ILC2s) express GATA-3 and related orphan receptor A (RORA) and secrete T H 2-associated cytokines, interleukin (IL)-5, and IL-13. Group 3 ILCs (ILC3s) utilize RORC (encoding RORgt) to drive production of the T H 17-associated cytokines, IL-17 and/or IL-22 (Serafini et al., 2015; Spits et al., 2013) . These different ILC subsets are found in diverse lymphoid and non-lymphoid tissues and enriched at mucosal sites where they play essential roles in barrier function and innate immune defense (Artis and Spits, 2015; Eberl et al., 2015) .
Human ILC subsets were first identified in secondary lymphoid tissues and subsequently reported in intestine, lung, liver, and skin (Juelke and Romagnani, 2016) . Two distinct populations of IFN-g-producing ILC1s have been described. A T-BET + cell expressing high levels of CD127 and CD161 has been identified in tonsil and inflamed intestine (Bernink et al., 2013) . In contrast, an intraepithelial ILC1 expressing NKp44 and CD103, but not CD127, resides at mucosal sites (Fuchs et al., 2013) . Both these ILC1s produce IFN-g in response to IL-12, but unlike NK cells, they show minimal EOMES expression. Human GATA-3 + ILC2s express the chemoattractant receptor CRTh2 as well as IL-25R and IL-33R (Mjö sberg et al., 2011) , are systemically distributed, and produce IL-5 and IL-13 under physio-and pathological situations (Kim and Artis, 2015) . Group 3 ILCs include RORgt + fetal lymphoid tissue-inducer (LTi) cells in fetal lymph nodes and spleen (Cupedo et al., 2009) as well as adult lineage -CD127 + CD117 + cells found in tonsils, intestine, spleen, skin, lung, endometrium, and decidua that produce IL-17A in response to IL-23 (Klose and Artis, 2016) . A subset of ILC3s express natural cytotoxicity receptors (NCRs) and are enriched in IL-22-producing cells (Cella et al., 2009; Satoh-Takayama et al., 2008) . Murine ILCs differentiate from hematopoietic stem cells (HSCs) via lymphoid progenitors to yield diverse ID2 + TCF-1 + PLZF + ILC precursors (ILCPs) in fetal liver (FL) and adult bone marrow (BM) (Constantinides et al., 2014; Yang et al., 2015) . Several TFs and signaling pathways regulate this process in mice (Serafini et al., 2015) ; in contrast, human ILC development is less well characterized (Juelke and Romagnani, 2016) . NK precursors (NKPs) have been identified in fetal liver, BM, cord blood (CB), and adult tonsil (Renoux et al., 2015) , whereas committed ILC3 precursors (ILC3P) are found in tonsil and intestinal lamina propria but not peripheral blood (PB), thymus, or BM (Montaldo et al., 2014) . A recent study identified tonsillar human RORgt + ILCPs that can develop into mature cytotoxic and helper ILCs (Scoville et al., 2016) . Interestingly, these human NKPs, ILC3Ps, and ILCPs were CD34 + and enriched in secondary lymphoid tissues but were rare or absent from the circulation. It was unclear how these CD34 + hematopoietic precursors were developmentally related to mature tissue-resident ILC subsets.
In this report, we have extensively characterized the phenotypic, molecular, and functional attributes of PB and tissue CD117 + ILCs. This included an in vitro study of over 1,300 ILC clonal cultures as well as an in vivo analysis using humanized mice. While ILCs with the CD117 + phenotype were previously proposed to represent human ILC3s Figure 1D ). Interestingly, circulating CD117 + ILCs express high levels of IL-1R1 and CD45RA and are CD69 À , whereas gutresident ILC3s are CD69 + but IL-1R1 À and CD45RA À ( Figure 1C and S1B). These observations suggest that PB CD117 + ILCs differ from bona fide ILC3s.
PB CD117 + ILCs also do not express proteins for TF that characterize other known mature ILC subsets, including T-BET or EOMES ( Figure 1C ), although a fraction expressed PLZF ( Figure S1B ). Accordingly, PB CD117 + ILCs failed to express markers associated with NK cells, ILC1 and ILC2, such as CD94, CD244, and CRTh2 ( Figure S1B ) and did not produce IFN-g or IL-13 after stimulation with pharmacological activators ( Figure 1D ). Taken together, these results suggest that PB CD117 + ILCs may represent an unusual ILC subset.
Transcription and Chromatin Landscapes of CD117 + ILCs Reveal an ILCP Profile
In order to further understand the identity of PB CD117 + ILCs, we profiled the transcriptomic and epigenetic landscapes of highly purified circulating CD117 + ILCs compared to CD34 + HSCs ( Figure 2A ). We performed chromatin immunoprecipitation (ChIP) followed by high-throughput sequencing using transposase-mediated tagmentation (ChIPm-seq) . To expose common and unique epigenetic features of CD34 + HSCs and CD117 + ILCs, we mapped histone H3 lysine 4 di-methyl modifications (H3K4Me2s), which marks both active and poised gene regulatory elements (GREs) (Koche et al., 2011) . We identified $18,000 and 35,000 GRE in CD117 + ILCs and CD34 + HSCs, respectively ( Figure 2B ; Table S1 ), the majority of which were located in introns and intergenic regions ( Figure S2A ). A significant number of H3K4Me2 + GREs were shared between the two cell types: 89% of GREs identified in CD117 + ILCs showed similar enrichment in HSCs and were associated with 13,159 genes of which many encoded housekeeping functions. Nevertheless, 11% of H3K4Me2 + GREs detected in CD117 + ILCs were absent in CD34 + HSCs, potentially regulating 2,283 genes. Pathway analysis of these genes revealed a strong enrichment for immune system and lymphocyte-related processes. Conversely, GREs only active in CD34 + HSCs were located near genes involved in more general pathways important for hematopoiesis, hemostasis, and platelet activation ( Figure 2C ). We compared the transcriptome of CD117 + ILCs and CD34 + HSCs. Clear differences in gene expression profiles emerged, with a large cluster of 1,540 genes expressed at substantially higher levels in CD117 + ILCs ( Figure 2D ; Figure S1 . Figure S2B ).
As both transcriptomic and epigenetic analyses of CD117 + ILCs identified strong lymphoid signatures, we intersected these datasets in order to gain insights into the developmental status and potential of CD117 + ILCs. A substantial proportion (26%) of the genes most highly expressed in CD117 + ILCs were located in the direct vicinity of a CD117 + ILC-specific GREs ( Figure 2E ; 1C , and S1B), we added IL-2, IL-7, and/or IL-1b to these cultures. While bulk cultures of CD117 + ILCs minimally expanded in the presence of IL-2 and IL-7, robust proliferation was observed when IL-1b was added to the cultures ( Figure S3A ). The overall cell yield was reduced by more than 100-fold in the absence of any one of these cytokines ( Figure S3A Figure S3C ). While the additional presence of cytokines that can drive ILC1/ NK (IL-12, IL-18), ILC2 (IL-25, IL-33), or ILC3 (IL-23) development did not further increase cell yield over that obtained with IL-2, IL-7, and IL-1b ( Figures 3B and S3A ), the addition of IL-12 clearly promoted the development of EOMES + CD94 + IFN-g-producing NK cells and IL-23 was critical for IL-17A-producing ILC3s (Figures 3A and S3D) . These results not only define a cytokine milieu that supports multi-lineage ILC and NK cell generation (IL-2, IL-7, IL-1b, IL-23) but also suggest that the PB CD117 + ILCs harbor multi-potent ILCPs. We further characterized circulating CD117 + ILCPs using a modified stromal cell-based culture system that is permissive for B cell, T cell, and myeloid cell development ( Figure 3C ) (Mohtashami et al., 2010) . Moreover, this system can extensively expand human NK cells and ILC subsets at the clonal level (Lim et al., 2016 Figure 3E ; Table S4 ). As these clones maintained a high level of CD117, but lacked other ILC markers, they may represent ILCPs that have not further differentiated ( Figure S3F ). Fourth, Notch signals clearly influence the cell fate potential of CD117 + ILCPs as multi-potentiality and development of ILC3-containing cells was enhanced on OP9-DL4 ( Figure 3E ; Table S4 ). Together, these data identify PB CD117 + ILCs as a circulating pool of partially committed ILC progenitors. The comparison of bulk and clonal assays clearly demonstrate the importance of the single-cell approach to define heterogeneity of CD117 + ILC cell fate potential and to establish functional multi-potency.
Circulating CD117 + ILCPs Have Multi-ILC Potential In Vivo in Humanized Mice
We next assessed the in vivo potential of PB CD117 + ILCPs.
Severely immunodeficient mouse strains engrafted with human CD34 + HSC progenitors generate human lymphoid (B, T, NK) and myeloid (DC, macrophage, neutrophils) cell subsets (reviewed in Rongvaux et al., 2013 Figure S2 and Tables S1, S2 , and S3. (B) Expansion of bulk cultured CD117 + ILCs (10 days) in stromal cell-free conditions with cytokines (20 ng/mL each). Results from four independent donors; not significant (ns), p > 0.05; **p < 0.01; ****p < 0.0001 using paired Student's t test compared to IL-2, IL-7 only condition (median).
(legend continued on next page) robust multi-lineage human hematopoietic cell engraftment, including NK cells (Legrand et al., 2011 Figure 4B ). These include mature ILC3s as previously described (Zhang et al., 2015 Figure 5B , data not shown) as previously described (Legrand et al., 2011; Zhang et al., 2015) . Moreover, within the subset of Lin À
CD7
+ cells, a clearly defined subpopulation of CD127 + CD117 + cells could be discerned in multiple tissues that lacked T-BET and EOMES expression (Figures 5B and 5C) . These included CD127 + CD117 + cells that expressed low levels of GATA-3 and RORgt and were NKp44 À ( Figure 5D ) and therefore resembled PB CD117 + ILCPs. Ex vivo stimulation failed to elicit cytokine production from CD127 + CD117 + cells ( Figure 5E ). We sorted these cells and cultured them in the presence of IL-2, IL-7, IL-1b, and IL-23. Expanded cells contained subsets able to produce IFN-g, IL-13, IL-17A, and IL-22 (Figure 5E (Rollini et al., 2007) and is proposed as a site for the development of lymphoid tissue inducer cells in the mouse (Cherrier et al., 2012) . Lin À CD127 + ILCs within fetal liver contain a predominant CD117 + subset ( Figure S4A ). Interestingly, these cells express RORgt at levels exceeding their peripheral blood counterparts ( Figures 1C and S4A ) and moreover express CCR6, neuropilin-1 (NRP-1), but not NKp44 ( Figures  S4A and S4B ). Despite these differences, fetal liver CD117 + ILCs did not produce significant amounts of IL-17A or IL-22 after stimulation ( Figure S4C ) suggesting that they were not fully mature ILC3. Nevertheless, when fetal liver CD117 + ILCs were expanded in vitro, IL-17A-producing ILC3s were abundantly generated. Moreover, IL17A + ILC3s developed on stromal cells lacking the Notch ligand DL4 suggesting that Notch engagement is not necessary for this process ( Figure 6A) (Figures S4A and S4B ). Bulk cultures of lung CD117 + ILCs generated diverse cytokine-producing ILC subsets and EOMES + NK cells ( Figure 6G ); further analysis using clonal assays defined the NKp44 À fraction of lung CD117 + ILCs as a mixture of uni-potent and multi-potent ILCPs (Figures  6H and 6I; Table S5 ). These results demonstrate that a variety of ILCPs, including multi-potent progenitors, are present in human mucosal tissues. See also Figure S3 and Table S4 .
(legend on next page)
ILCPs Reside within Secondary Lymphoid Tissues As human secondary lymphoid tissues (lymph nodes, tonsils) harbor diverse ILC subsets and their precursors, we further characterized tonsillar CD117 + ILCPs and assessed their cell fate potential. CD117 + ILCs from pediatric tonsils harbor a predominant NKp44 + ILC3 subset that can be stimulated to produce IL-17A
and IL-22 (Hoorweg et al., 2012) . This population also appears to have extensive functional plasticity as stimulation (using IL-1b, IL-12, IL-23) modifies their cytokine production (Bernink et al., 2013 (Bernink et al., , 2015 Cella et al., 2010 Figure S4B ).
These findings suggest that NKp44 + ILC3s are more mature (Bernink et al., 2015) . However, cytokine production profiles were different in bulk cultures from tonsillar NKp44 À versus NKp44 + CD117 + ILCs ( Figure 6J and 6M). In particular, IFN-g + cells and IL-13 + cells were more obvious in cultures derived from NKp44 À cells, especially on OP9 stroma ( Figure 6J ).
In order to better understand the relationship between NKp44
À and NKp44 + CD117 + ILCs, we generated clones from both subsets and analyzed their cytokine-production potential. Striking differences were observed. Clones derived from NKp44 + CD117 + ILCs were highly enriched ILC3s producing IL-17A
and/or IL-22 (Figures 6N and 6O ; Table S5 ). A fraction of clones co-expressed IFN-g (14%) that likely represent ''plastic'' ILC3s that may upregulate T-BET as previously shown (Bernink et al., 2015) . press the TF RORC (Scoville et al., 2016) . In order to address whether RORC is required for generation of human CD117 + ILCPs, we studied blood ILCs in RORC-deficient patients. RORC deficiency in humans is associated with mycobacterial disease and mucocutaneous candidiasis and a defect in Th1 and Th17 differentiation (Okada et al., 2015) . CD117 + ILCs are reduced in patients with RORC deficiency, while CD56 bright and CD56 dim NK cells were unaffected ( Figures 7A and 7B ). In contrast, ILC1s were present and the percentage of ILC2s from total ILCs was significantly increased in the absence of RORC ( Figure 7B ). Sorted CD117 + ILCs from control and RORC-deficient patients were cultured as described above. Robust growth of Lin À CD7 + cells was observed with no significant difference between WT and RORC-deficient cells. We identified diverse cytokine producing cells in these cultures, including those producing IFN-g, IL-13, or IL-22, however, there was a total absence of IL-17A-producing ILC3s ( Figure 7C) BM, as well as cord and adult blood (Scoville et al., 2016) suggests that CD34 + ILCPs arise locally. The circulating and tissue CD34 À ILCPs that we describe also harbor cells with more restricted uni-potent ILCs. While we have not identified a marker that allows distinction between multi-potent and unipotent ILCPs, we assume that they retain a precursor-product relationship.
Transcriptomic and epigenomic analysis of circulating human ILCPs revealed a signature consistent with a partial specification to the ILC lineage. TFs known to be critical for ILC development in mice (including TCF7, TOX, ID2, ZBTB16, and GATA3) (Constantinides et al., 2014; Klose et al., 2014; Seehus et al., 2015; Serafini et al., 2014; Yagi et al., 2014; Yang et al., 2015) were clearly upregulated in ILCPs compared to circulating HSCs. In contrast, signatures of early B and T lymphopoiesis were not obvious, consistent with the inability of ILCPs to generate adaptive lymphocytes in vitro or in vivo. Previous studies have carefully analyzed the epigenomic and transcriptional landscape of human mucosal ILC subsets (Koues et al., 2016) . These studies identified distinct transcriptional signatures for ILC1, ILC3, and conventional NK cells as well as shared gene circuitry associated with ILC lineage differentiation under the control of defined ''super enhancers' ' (Koues et al., 2016) . In contrast, we find that the ILC group-defining TFs (BCL11B, TBX21, EOMES, RORC) and effector molecules (IFNG, IL13, IL17A, IL22, IL26) identified by Koues et al. (2016) were not expressed by circulating ILCPs (Table S2) , suggesting commitment to ILC1, ILC2, or ILC3 had not yet occurred. Interestingly, the loci encoding these factors were still ''poised'' as evidenced by abundant H3K4Me2 epigenetic modifications consistent with establishing of ILC ''regulomes'' at an early developmental stage (Shih et al., 2016) . This chromatin landscape likely facilitates rapid generation of differentiated ILC subsets following cytokine-driven expansion (LaraAstiaso et al., 2014; Zook et al., 2016) .
Mature ILCs and fully differentiated T H cells possess striking similarities (Spits et al., 2013) . T H cells arise following antigen activation of naive T cells within specialized zones of secondary lymphoid tissues. While the analogous sites and structures that promote ILC differentiation are not known, it is interesting to consider circulating and tissue ILCPs as the functional innate counterpart of naive T cells. Both naive T cells and ILCPs are CD45RA + and CD69 À suggestive of a resting state. Human
and mouse ILCPs clearly demonstrate the potential for further differentiation to all known ILC subsets and lack expression of the signature TFs that drive mature ILC effector functions. As such, ILCPs resemble naive T cells that can differentiate to diverse T helper subsets under appropriate environmental signals. Nevertheless, human ILCPs have signature TFs in a poised state that contrasts with the situation in naive T cells where these loci are actively repressed (Shih et al., 2016) . Moreover, ILCPs expand extensively in the presence of cytokines, whereas naive T cell homeostasis is primarily maintained through cytokinedriven survival (Marrack and Kappler, 2004) . Taken together, ILCPs appear to have some properties in common with naive T cells, although a number of important differences exist that are consistent with their designation as immature progenitors. While uni-potent and multi-potent ILCPs were identified in every human tissue sample tested, there were clearly differences in the relative proportions of ILCPs that were uni-or multi-potent. It is therefore likely that each tissue harbors a unique ILCP ''repertoire'' conditioned by environmental signals. Notch signals appear to influence ILCP multi-potency and ILC3 fate, particularly in the fetal liver. It is remarkable that other uni-potent ILCPs were rarely detected in this organ, suggesting that at this stage of fetal development, the microenvironment may deliver signals that strongly polarize ILCPs toward ILC3s. These results corroborate earlier findings in the mouse (Cherrier et al., 2012) . Notch-mediated signaling has been proposed to play a role in directing lymphoid cell fate decisions, promoting the development of T-lineage primed precursors, as well as modifying ILCPs homeostasis (Chea et al., 2016; Dallas et al., 2005) . Soluble factors are also likely to be involved in ILCPs ''repertoires'' as these cells express several cytokine receptors (IL-1R, IL-2R, IL-18R) that allow them to sense tissue inflammation and stress.
Regulation of TF expression dictates ILC fate as well as function. Signature TFs have been identified for ILC subsets that regulate their differentiation at the level of surface phenotype and effector outputs (Serafini et al., 2015) . The TF RORC helps define the ILC3 subset and is required for ILC3 development and maintenance in mice (Satoh-Takayama et al., 2008; Sawa et al., 2010) . RORC is expressed by human ILC3 and in committed ILC3P (Montaldo et al., 2014) . The recent report that all human ILC subsets express RORC (Scoville et al., 2016) suggested a broader role for this TF in human ILC differentiation. By analyzing blood from RORC-null patients, we could show that RORC was not required for global ILC differentiation in humans, but rather was critical for IL-17 production by the ILC3 subset. ILCPs in RORC-deficient patients retained the capacity to generate other cytokine-producing ILC and NK cell subsets. It is noteworthy that IL-22 + ILC3s developed in a RORC-independent fashion, suggesting compensatory pathways for these cells in humans.
We have previously shown that OP9 stroma minimizes human ILC2 plasticity (Lim et al., 2016) and extend this observation by showing that in this culture system the vast majority of NKp44 + ILC3 clones retain their functional attributes with little plasticity toward the ILC1 phenotype. Moreover, previous reports proposed that ILC1 clones rapidly differentiate toward an ILC3 fate in the presence of IL-1b (Bernink et al., 2015) , whereas we found that ILC1 clones on OP9 stroma (containing IL-1b) retained their IFN-g signature. As such, our culture system appears useful to assess signals that promote ''primary'' ILC fate from ILCPs.
Finally, our identification of circulating and tissue-resident human ILCPs suggests a concept of ''ILC-poiesis'' in which See also Figure S5 .
ILC differentiation can occur ''on demand'' in any tissue and at any age. A recent study using parabiosis in mice has proposed that ILCs are long-lived tissue-resident cells that do not recirculate under steady state and some inflammatory conditions (Gasteiger et al., 2015) . In contrast, the half-life of several mucosal ILC subsets in the mouse is on the order of weeks, suggesting that these cells must be renewed (Sawa et al., 2010) . The discovery of a circulating ILCPs provides a mechanism to replenish tissue ILCs in response to steady-state losses and in the context of infection and inflammation.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human blood and tissues samples Blood samples from healthy donors were obtained from Establissement Franç ais du Sang (EFS, Paris). Blood samples from patients with RORC mutation have been previously reported (Okada et al., 2015) including P2 from Kindred A (homozygous for S38L/38L isoform 1 or S17L/S17L isoform 2) and P6 from Kindred C (homozygous for Q441* isoform 1 or Q420* isoform 2). Fetal liver with gestational age ranging from 14 to 20 weeks were obtained from In vivo analysis using human immune system (HIS) mice model BALB/c Rag2 -/-Il2rg -/-Sirpa NOD (BRGS) mice have been described (Legrand et al., 2011) and were maintained in isolators at Institut Pasteur. CD34 + HSC or CD117 + ILC were sorted from peripheral blood of healthy donors using a FACS Aria. Fetal liver CD34 + HSC were isolated using CD34 Microbead Kit (Miltenyi). For in vivo transfer experiment, 1-3 3 10 5 CD117 + ILC or CD34 + HSC were intrahepatically injected into sublethal irradiated (3Gy) new born (3-7 days-old) BRGS mice together with 0.3 mg of IL-2 and IL-7 (Miltenyi). Mice received IL-2, IL-7, IL-1b, and IL-23 (0.3 mg each) by intraperitoneal injection weekly and were analyzed four weeks posttransplantation. For generation of HIS mice, 2 3 10 5 fetal liver-derived CD34 + CD38 -HSC were intrahepatically injected into sublethal irradiated (3Gy) new born (3-7 days-old) BRGS mice. Mice were sacrificed 8-9 weeks post-injection. Experiments were approved by ethical committee at Institut Pasteur and validated by French Ministry of Education and Research (MENESR#02162.02).
METHOD DETAILS
Cell isolation from blood, tonsil, gut, fetal liver, and lung Human peripheral blood mononuclear cells (PBMC) from CB and PB were isolated by Ficoll-Paque (GE Healthcare) density gradient centrifugation. Single cell suspension from fetal liver and tonsil was achieved by mechanical disruption through 70-mm filters. Lung and intestine samples were minced and digested with Liberase TL (25 mg/ml; Roche) and DNase I (50 mg/ml; Sigma-Aldrich) for 45min in 37 C shaking incubator. Digested tissues were passed through 70-mm filters. Lymphocytes from liver, lung, and gut were isolated by Ficoll-Paque density gradient centrifugation.
FACS analysis and cell sorting
For FACS analysis, cells were first stained with Flexible Viability Dye eFluor 506 (eBioscience) for 10 min following by 20 min surface antibodies staining with Brilliant Stained Buffer (BD) on ice. For experiment involving intracellular TF staining, cells were fixed, permeabilized, and stained using Foxp3/Transcription Factor Staining Buffer Kit (eBioscience). For intracellular cytokines staining, cells were stimulated with PMA (10ng/ml; Sigma) plus Ionomycin (1 mg/ml; Sigma) in the presence of Golgi Plug (BD) for 3 hr in 37 C incubator. Cells were fixed, permeabilized, and stained by Cytofix/Cytoperm Kit (BD). Samples were acquired on LSRFortessa (BD) and analyzed by FlowJ10 (Tree Star).
For cell sorting from healthy PB, PBMC were first depleted of T cell, B cell, pDC and monocytes by labeling with biotin-conjugated anti-CD3, anti-CD4, anti-CD19, anti-CD14, anti-CD123 followed by anti-biotin microbeads (Miltenyi) according to manufacturer's instructions. Sorting from CB and tissues were performed without lineage depletion. Bulk populations were sorted to a purity R 99% or as single cell index sorting (both using FACSAria II; BD).
Bulk RNA isolation, library construction, sequencing, and analysis 10 3 cells from each population were FACS sorted directly into 50 mL of lysis/binding buffer (Life Technologies). mRNA was captured with 15 mL Dynabeads oligo(dT) (Life Technologies), washed according to manufacturers' instructions and eluted at 85 C with 6 mL of 10mM Tris-HCl (pH7.5). We used a derivation of MARS-Seq as described (Jaitin et al., 2014) , developed for single-cell RNA-seq to produce expression libraries of two replicates per population. Libraries were sequenced at an average depth of 5 million reads per library on the Ilumina NextSeq and aligned to the human reference genome (hg19). Reads were mapped using hisat (version 0.1.6); duplicate reads were filtered if they had identical UMIs. Expression levels were calculated and normalized to the total number of reads using HOMER software (http://homer.salk.edu).
Bulk and single cell culture All in vitro culture experiments were performed in Yssel's medium supplemented with 2% human AB serum (EFS). 2-3 3 10 3 stromal cells were pre-seeded in 96-well round bottom plates one night before culture. For bulk culture, 100-300 FACS sorted cell were plated on the stromal cells. For cloning experiment, cells were index-sorted directly into the 96-well plates pre-seeded with stromal cells. Cytokines IL-2, IL-7 (20 ng/ml each, Miltenyi), IL-12, IL-18, IL-25, IL-33, IL-1b, IL-23 (20 ng/ml each, R&D) were provided in various combinations as indicated. For bulk culture, fresh cytokines and medium were replenish every 5 days and analyzed after 10 days expansion. For cloning experiment, cytokines and medium were replenished every 7 days and analyzed after 14-18 days of culture.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are represented as Median unless specified. The sample size for each experiment and the replicate number of experiments are included in the figure legends.
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Data Resources
The accession number for the RNA-Seq and ChIPm-Seq analysis have been deposited in the NCBI Gene Expression Omnibus under accession numbers GEO: GSE90834 and GEO: GSE90640.
ADDITIONAL RESOURCES Yssel's Medium
Yssel's Medium is prepared in house by using IMDM (Invitrogen) plus 0.25% (w/v) bovine serum albumin (Sigma), 1.8 mg/L 2-amino ethanol, 40 mg/L Apo-transferrin, 5 mg/L insulin and penicillin/Streptomycin. 
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